Cancer Management Guidelines
-
Acute Lymphoblastic Leukemia (ALL)
Publications
Updated: September 2010
2009
- Abou Mourad YR, Karfan-Dabaja MA, Song KW, Nantel SH. Allogeneic Stem Cell Transplantation in Adult Acute Lymphoblastic Leukemia: a Comprehensive Review. Current Medical Literature, 17(1): 1-11, 2009.
Abou Mourad 2009 Allo SCT in Adult ALL - A Comprehensive Review
2008
- Abou Mourad YR, Fernandez HF, Kharfan-Dabaja MA. Allogeneic Hematopoietic Cell Transplantation for Adult Philadelphia-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. Biol Blood Marrow Transplant, 14: 949-958, 2008.
Abou Mourad 2008 Allo HCT for Ph ALL in the Era of TKI
Prior to 2008
- Barry E, Deangelo DJ, Neuberg D, Stevenson K, Loh ML, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin M, Cohen HJ, Sallan SE & Silverman LB. Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated with Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 25: 813-819, 2007.
Barry 2007 Favorable Outcome for Adolescents Treated with Dana-Farber ALL Consortium Protocols - Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, McMillan AK, Tallman MS, Rowe JM & Goldstone AH. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109: 944-950, 2007.
Fielding 2007 Outcome of 609 adults after relapse of ALL (MRC UKALL12 ECOG 2993) - Moorman AV, Harrison CJ, Buck GAN, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH & Dewald GW. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 109: 3189-3197, 2007.
Moorman 2007 Karotype Prognosis (MRC UKALL12 ECOG 2993) - Rowe JM, Buck G, Burnett AK, Chopra R, Wiemik PH, Richards SM, Lazarus HM, Franklin IM, Litzow MR, Ciobanu N, Prentice G, Durrant J, Tallman MS & Goldstone AH. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 106: 3760-3767, 2005.
Rowe 2005 Induction Therapy Results of 1500 ALL Patients (MRC UKALL12 ECOG E2993) - Thomas X, Boiron J-M, Huguet F, Dombret H, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Vernant J-P, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lheritier V & Fiere D. Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial. J Clin Oncol 22: 4075-4086, 2004.
Thomas 2004 Outcome of Treatment Analysis_LALA-94 Trial - Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, Ferrara F, Antonio P, Ciolli S, Deplano W, Fabbiano F, Sica S, Di Raimondo F, Cascavilla N, Tabilio A, Leoni P, Invernizzi R, Baccarani M, Rotoli B, Amadori S, Mandelli F. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 99: 869-871, 2002.
Annino 2002 Long-term Follow-up of the GIMEMA ALL 0288 Trial
| The information contained in these guidelines is a statement of consensus of Leukemia/BMT Program of BC professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these guidelines and documents is at your own risk and is subject to the Leukemia/BMT Program of BC’s terms of use available at Terms of Use. |